疑似前列腺癌患者以MRI作为一线检查在常规实践中的诊断检出率
研究纳入262例疑似前列腺癌男性,以多参数前列腺MRI作为一线检查,记录按PI-RADS分类的ISUP≥2癌症检出率。PI-RADS 1-2、3、4、5的ISUP≥2检出率分别为8%、18%、49%、80%;阳性患者中检出率随PSA密度升高而增加。作者结论为三分之一男性可避免活检,采样肿瘤非相邻的正常表现区可能不必要。
要点
- PI-RADS 1-2者ISUP≥2检出率8%(5/61),三分之一男性可避免活检。
- PI-RADS 3、4、5的ISUP≥2检出率分别为18%(3/17)、49%(22/45)、80%(72/90)。
- PI-RADS 5中PSA密度≥0.15组ISUP≥2为89%,高于<0.12组的40%。
核心结论
- 阴性MRI(PI-RADS 1-2)后约三分之一男性可避免活检。
- 在MRI阳性疑似分类内,癌症检出率随PSA密度值升高而增加。
- 采样肿瘤非相邻的正常表现区可能对全腺治疗不必要。
研究设计与样本
- 单中心常规实践研究,纳入疑似前列腺癌转诊至二级医疗的男性262例,其中90.5%为活检初治。
- 以多参数前列腺MRI作为一线检查,行系统经直肠前列腺活检,伴或不伴认知靶向活检。
- 记录按PI-RADS分类的ISUP≥2癌症诊断检出率,并评估PSA密度对活检结果的影响。
诊断标准与关键数值
- 262例中86例(33%)MRI阴性(PI-RADS 1-2),176例(67%)阳性(PI-RADS 3占8%、PI-RADS 4占21%、PI-RADS 5占38%)。
- 262例中213例接受活检,ISUP≥2检出率PI-RADS 1-2为8%(5/61)、PI-RADS 3为18%(3/17)、PI-RADS 4为49%(22/45)、PI-RADS 5为80%(72/90)。
- 阳性患者中ISUP≥2比例随PSA密度升高:PI-RADS 3在PSA密度<0.12、0.12至<0.15、≥0.15组分别为0%、0%、25%。
- PI-RADS 4在PSA密度<0.12、0.12至<0.15、≥0.15组ISUP≥2分别为21%、33%、68%。
- PI-RADS 5在PSA密度<0.12、0.12至<0.15、≥0.15组ISUP≥2分别为40%、83%、89%。
临床应用与阅片要点
- 报告MRI时应给出PI-RADS分类,并结合PSA密度评估活检检出风险。
- 采样正常表现的肿瘤非相邻六分区未使腺体水平组织学从无显著意义升级为有临床意义前列腺癌。
- 作者认为采样肿瘤非相邻的正常表现六分区对全腺治疗可能不必要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To document cancer yields of magnetic resonance imaging (MRI)-directed biopsies in men with suspected prostate cancer referred to secondary care.
MATERIALS AND METHODS: Men with suspected cancer undergoing multiparametric prostate MRI as the first-line investigation were included in the present study. Systematic transrectal prostate biopsies with/without cognitive targeted biopsies were performed. Diagnostic yields of International Society of Urological Pathology (ISUP) ≥2 cancers by the Prostate Imaging Reporting and Data System (PI-RADS) category were recorded. Impacts of prostate-specific antigen (PSA) density on biopsy results and yields of non-targeted biopsies in MRI non-suspicious prostate sextants assessed.
RESULTS: Of 262 men (90.5% biopsy naive), 86 (33%) MRI examinations were negative (PI-RADS 1-2) and 176 (67%) positive (PI-RADS 3: 8%; PI-RADS 4: 21%; PI-RADS 5: 38%). Two hundred and thirteen of 262 patients underwent a biopsy. ISUP ≥2 cancer detection rates were 8% (5/61) for PI-RADS 1-2, 18% (3/17) for PI-RADS 3, 49% (22/45) for PI-RADS 4, and 80% (72/90) for PI-RADS 5. Proportions of ISUP ≥2 increased with higher PSA densities in positive patients (%ISUP ≥2 for PSA density groups <0.12, 0.12 to <0.15 and ≥ 0.15 was 0%, 0%, 25% for PI-RADS 3, 21%, 33%, 68% for PI-RADS 4 and 40%, 83%, 89% for PI-RADS 5 respectively). ISUP ≥2 cancers were twice as likely in tumour adjacent sextants (52% versus 24%), without upgrading of gland level histology from insignificant to clinically significant prostate cancer by the sampling of normal-appearing tumour non-adjacent sextants.
CONCLUSIONS: One third of men can avoid biopsy after negative MRI. Cancer detection rates increase with PSA density values within positive MRI suspicion categories. Sampling normal-appearing tumour non-adjacent sextants may be unnecessary for whole-gland therapy.
引用
- Sokhi HK, Padhani AR, Patel S, et al. Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice. Clin Radiol. 2020. PMID: 32919755. doi:10.1016/j.crad.2020.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。